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Single	   nucleotide	   polymorphisms	   on	   chromosome	   4q25	   have	   been	   associated	   with	   risk	   of	   atrial	  
fibrillation	   (AF).	   However,	   the	   exiguous	   knowledge	   of	   the	   mechanistic	   links	   between	   these	   risk	  
variants	  and	  underlying	  electrophysiological	  alterations	  hampers	  their	  clinical	  utility.	  Here,	  we	  used	  
RT-­‐PCR	  analysis,	  western	  blotting,	  confocal	  calcium	  imaging,	  and	  patch-­‐clamp	  techniques	  to	  identify	  
mechanisms	   linking	   4q25	   risk	   variants	   rs2200733T,	   rs13143308T	   or	   rs1448818G	   to	   defects	   in	   the	  
calcium	  homeostasis	  observed	  in	  AF.	  Our	  findings	  revealed	  that	  the	  rs13143308T	  variant	  was	  more	  
frequent	   in	   patients	   with	   AF	   and	   that	   it	   was	   associated	   with	   a	   significantly	   higher	   sarcoplasmic	  
reticulum	  (SR)	  calcium	  ATPase	  expression,	  SR	  calcium	   load,	  calcium	  spark	  density	  and	  spontaneous	  
electrical	   activity	   than	   the	   normal	   rs13143308G	   variant.	   Additionally,	   pitx2c	   expression	   was	  
depressed	  in	  rs13143308T	  carriers,	  and	  a	  transgenic	  mouse	  model	  with	  atrial-­‐specific	  heterozygous	  
PITX2C	  deficiency	  faithfully	  reproduced	  the	  alterations	  in	  calcium	  homeostasis	  and	  electrical	  activity	  
observed	  in	  rs13143308T	  carriers,	  supporting	  a	  regulatory	  role	  for	  pitx2c.	  Thus,	  we	  identify	  the	  4q25	  
variant	   rs13143308T	   as	   a	   genetic	   risk	  marker	   for	  AF,	   specifically	   associated	  with	   excessive	   calcium	  
release	  and	  spontaneous	  electrical	  activity	  caused	  by	  alterations	  in	  the	  expression	  and	  activity	  of	  SR	  
calcium	  regulatory	  proteins,	  and	  possibly	  induced	  by	  deficient	  pitx2c	  expression	  in	  carriers	  of	  this	  risk	  
variant.	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  INTRODUCTION:	  	  
Atrial	   fibrillation	   (AF)	   is	   the	  most	   common	   cardiac	   arrhythmia	   and	   a	  major	   contributory	   factor	   to	  
increase	  mortality	   and	   risk	   of	   cerebrovascular	   embolism(1).	   Unfortunately,	   current	   treatments	   are	  
often	  deficient	  or	  ineffective.	  	  
A	  number	  of	  electrophysiological,	  molecular,	  and	  structural	  alterations	   take	  place	   in	   the	   fibrillating	  
atria	   that	   favor	   the	   maintenance	   and	   self-­‐perpetuation	   of	   the	   arrhythmia(2,	   3).	   	   Among	   the	  
electrophysiological	   alterations,	   several	   studies	   have	   reported	   disturbances	   in	   the	   calcium	  
homeostasis(4-­‐7)	   and	   malfunctioning	   of	   the	   sarcoplasmic	   reticulum	   (SR)(4,	   5,	   7-­‐10).	   Indeed,	  
myocytes	  from	  patients	  with	  AF	  depict	  a	  high	  rate	  of	  spontaneous	  SR	  calcium	  release(4),	  which	  has	  
been	   linked	   to	   deficient	   phosphodiesterase	   activity(11),	   reduced	   phosphatase	   activity(12),	   or	  
excessive	  protein	  kinase	  A-­‐(5,	  9)	  or	  calmodulin	  kinase	  type	   II-­‐dependent(8,	  10,	  13)	  phosphorylation	  
of	   the	   cardiac	   ryanodine	   receptor	   (RyR2).	   Importantly,	   spontaneous	   calcium	   waves	   can	   induce	  
arrhythmogenic	  membrane	  depolarizations	   in	  atrial	  myocytes	   from	  patients	  with	  AF(10),	  and	  occur	  
both	   in	   resting	   and	   electrically	   stimulated	   human	   atrial	   myocytes(14,	   15).	   Moreover,	   transgenic	  
mouse	   models	   with	   high	   rates	   of	   spontaneous	   calcium	   release	   are	   more	   prone	   to	   present	  
arrhythmia(10,	   16-­‐18);	   supporting	   the	   notion	   that	   spontaneous	   SR	   calcium	   release	   plays	   a	   central	  
role	  in	  these	  arrhythmogenic	  processes.	  	  
Thus,	  electrophysiological	  mechanistic	   studies	  are	  narrowing	  down	  the	  molecular	  mechanisms	  that	  
underlie	   defective	   calcium	   homeostasis	   in	   AF.	   Still,	   specific	   molecular	   triggers	   of	   AF	   are	   not	   well	  
defined,	  except	  from	  mutations	  in	  ion	  channels	  associated	  to	  familial	  AF(19-­‐21)	  that	  only	  account	  for	  
a	  minority	  of	  the	  patients	  with	  AF.	  However,	  genome	  wide	  association	  studies	  have	  identified	  several	  
single	  nucleotide	  polymorphisms	  (SNP)s	  on	  chromosomes	  4q25,	  1q21	  and	  16q22	  that	  are	  associated	  
with	   AF(22,	   23)	   and	   recent	  meta-­‐analyses	   have	   further	   expanded	   the	   number	   of	   risk	   variants(24).	  
The	  most	  striking	  arrhythmogenic	  variants	  remain	  those	  located	  at	  4q25(25)	  and	  some	  of	  them	  have	  
been	   reported	   to	  modify	   the	   risk	  of	  AF	   recurrence	  after	   catheter	  ablation(26)	  and	   the	   response	   to	  
 4 
antiarrhythmic	  drug	  treatment(27).	  Furthermore,	  since	  the	  bicoid-­‐related	  homedomain	  transcription	  
factor	   Pitx2	   plays	   a	   critical	   role	   in	   cardiac	   development,	   and	   is	   located	   in	   the	   vicinity	   of	   the	   4q25	  
variants,	   Gudbjartsson	   et	   al.(22)	   postulated	   that	   Pitx2	   dysfunction	   could	   be	   the	   molecular	   link	  
between	  risk	  variants	  at	  4q25	  and	  AF.	  While	  studies	  have	  examined	  Pitx2	  expression	  in	  patients	  with	  
4q25	   risk	   variants(28,	   29)	   and	   in	   patients	   with	   AF(29-­‐31)	   the	   results	   from	   these	   studies	   are	  
inconclusive	   regarding	   the	   link	  between	  4q25	   risk	  variants,	  Pitx2	   function,	  and	  AF;	   thus	  hampering	  
stratification	  and	  treatment	  based	  on	  the	  4q25	  genotype.	  
On	   the	   other	   hand,	   no	   studies	   have	   so	   far	   investigated	   if	   the	   4q25	   risk	   variants	   entail	  
electrophysiological	   disturbances	   that	   are	   commonly	   associated	   to	   functional	   alterations	   in	   the	  
intracellular	   calcium	   homeostasis.	   Therefore,	   we	   here	   tested	   the	   hypothesis	   that	   risk	   variants	   on	  
chromosome	   4q25	   are	   genetic	   triggers	   of	   alterations	   in	   the	   intracellular	   calcium	   homeostasis	  





4q25	  risk	  variants	  in	  the	  study	  population	  
Genotyping	  was	  done	  in	  543	  patients	  for	  the	  4q25	  risk	  variants	  rs2200733T	  and	  rs13143308T	  that	  are	  
highly	   associated	   with	   AF	   risk(22,	   32)	   and	   subsequently	   in	   253	   patients	   for	   the	   rs1448818G	   risk	  
variant	   that	   is	   closer	   to	   the	   PITX2	   locus(33).	   The	   rs13143308T	   risk	   variant	   was	   more	   frequent	   in	  
patients	  with	  AF	  (p=0.005)	  while	  risk	  variants	  rs2200733T	  and	  rs1448818G	  depicted	  non-­‐significant	  
trends	   (supplementary	   figure	   1).	   The	   rs2200733T	   risk	   variant	   co-­‐segregated	   with	   rs13143308T	  
(p<0.001;	   supplementary	   figure	  2A),	  whereas	   there	  was	  no	  significant	  co-­‐segregation	  of	   rs2200733	  
with	   rs1448818	   or	   rs13143308	   with	   rs1448818	   (supplementary	   figure	   2B-­‐C).	   Atrial	   tissue	   samples	  
and/or	   myocytes	   from	   280	   of	   these	   patients	   were	   used	   for	   further	   genetic,	   electrophysiological	  
and/or	   molecular	   biological	   analysis.	   The	   clinical	   and	   echocardiographic	   data	   as	   well	   as	  
pharmacological	  treatments	  of	  these	  patients	  are	  summarized	  in	  Table	  1.	  
Impact	  of	  the	  4q25	  risk	  variant	  rs13143308T	  on	  spontaneous	  electrical	  activity	  
Since	  the	  rs2200733	  and	  rs13143308	  variants	  have	  repeatedly	  been	  associated	  with	  increased	  risk	  of	  
AF,	  our	  analysis	  initially	  focused	  on	  these	  variants.	  However,	  since	  the	  two	  variants	  are	  located	  next	  
to	  each	  other30	  and	  the	  rs2200733T	  risk	  variant	  occurred	  together	  with	  the	  rs13143308T	  risk	  variant	  
in	  myocytes	   isolated	   from	  all	  but	  one	  of	   the	  patients,	   the	  specific	  effect	  of	   the	  rs2200733T	  variant	  
could	   not	   be	  measured	   directly.	   Therefore,	   analysis	   initially	   focused	   on	   how	   the	   rs13143308T	   risk	  
variant	  affected	  calcium	  homeostasis.	  First,	  we	  analyzed	  the	  frequency	  of	  transient	  inward	  currents	  
(ITI)	   resulting	   from	   extrusion	   of	   spontaneously	   released	   calcium	   by	   the	   Na-­‐Ca	   exchanger	   (NCX).	   In	  
patients	  without	  AF,	  the	  ITI	  frequency	  was	  significantly	  higher	  in	  myocytes	  from	  patients	  carrying	  the	  
rs13143308T	   risk	   variant	   (Figure	   1A-­‐B)	   while	   the	   ITI-­‐amplitudes	  were	   similar	   for	   patients	   with	   and	  
without	  risk	  alleles	  (Figure	  1C).	  Current-­‐clamp	  experiments,	  performed	  in	  myocytes	  from	  a	  subset	  of	  
patients	   to	   determine	   the	   net	   impact	   of	   calcium	   release-­‐induced	   Na+-­‐Ca2+	   exchange	   on	   the	  
membrane	   potential,	   showed	   a	   higher	   amplitude	   and	   frequency	   of	   spontaneous	   membrane	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depolarizations	   in	  carriers	  of	   the	  risk	  variant	   (Figure	  1D-­‐F).	   In	  two	  of	   the	  patients	  with	  risk	  variants	  
some	  of	  the	  membrane	  depolarizations	  were	  large	  enough	  to	  trigger	  spontaneous	  action	  potentials.	  
Impact	  of	  the	  4q25	  risk	  variant	  rs13143308T	  on	  calcium	  homeostasis	  
Using	  frame-­‐scanning	  confocal	  calcium	  imaging	  to	  visualize	  local	  calcium	  release	  from	  RyR2	  clusters	  
(calcium	   sparks)	   in	   a	   longitudinal	   plane	   of	   the	   myocyte	   revealed	   that	   the	   spark	   frequency	   was	  
significantly	  higher	  in	  patients	  carrying	  a	  rs13143308T	  risk	  variant	  than	  in	  those	  with	  normal	  variants	  
at	  rs2200733	  and	  rs13143308	  (figure	  2A-­‐B).	  This	  was	  due	  to	  a	  higher	  density	  of	  spark	  sites	  (Figure	  2C)	  
rather	  than	  a	  higher	  firing	  frequency	  per	  site	  (Figure	  2D).	  Analysis	  of	  the	  spark	  properties	  (figure	  3A-­‐
B)	  showed	  that	  the	  4q25	  risk	  variants	  did	  not	  affect	  the	  spark	  amplitude	  (Figure	  3C),	  duration	  (Figure	  
3D)	  or	  width	  (Figure	  3E).	  
Immuofluorescent	   labeling	   of	   total	   and	   ser2808	   phosphorylated	   RyR2	   clusters	   revealed	   that	   the	  
presence	   of	   a	   risk	   variant	   did	   not	   affect	   the	   density	   of	   RyR2	   clusters	   (0.59±0.10	   vs.	   0.56±0.07	  
clusters/µm2)	   but	   it	   significantly	   increased	   the	   ser2808/RyR2	   intensity	   ratio,	   suggesting	   that	   the	  
rs13143308T	   variant	   favors	   RyR2	   phoshporylation	   at	   ser2808	   (Figure	   4A).	   Measurements	   of	   the	  
caffeine	  releasable	  SR	  calcium	  load	  from	  the	  time-­‐integral	  of	  the	  caffeine	  induced	  NCX	  current	  were	  
also	  significantly	  higher	   in	  atrial	  myocytes	  from	  patients	  with	  a	  4q25	  risk	  variant	  (Figure	  4B),	  which	  
could	   potentially	   increase	   the	   number	   of	   RyR2	   clusters	   that	   reach	   the	   threshold	   for	   spontaneous	  
calcium	   release	   and	   thereby	   the	   density	   of	   calcium	   spark	   sites.	   By	   contrast,	   plotting	   the	  NCX	   rate	  
against	  the	  calcium	  available	  for	  extrusion	  by	  the	  NCX	  to	  assess	  the	  NCX	  activity	  (see	  supplementary	  
figure	  3	  for	  details)	  showed	  no	  difference	  between	  the	  resulting	  slopes	  for	  patients	  with	  normal	  and	  
risk	  variants	  (Figure	  4C).	  
Western	  blot	  analysis	  of	  SR	  calcium	  regulatory	  proteins	  revealed	  that	  expression	  of	  the	  cardiac	  sarco-­‐
endoplasmatic	   reticulum	   calcium	   ATPase	   (SERCA2a)	   was	   significantly	   higher	   in	   patients	   with	   a	  
rs13143308T	   risk	   variant	   (Figure	   4D)	   while	   expression	   of	   the	   SR	   calcium	   buffering	   protein	  
calsequestrin-­‐2	  (CSQ-­‐2)	  and	  the	  NCX	  were	  similar	  in	  patients	  with	  and	  without	  risk	  variants.	  
Combined	  and	  independent	  effects	  of	  the	  rs13143308	  risk	  variant	  and	  atrial	  fibrillation	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To	  determine	   if	   the	   rs13143308T	   risk	   variant	   exacerbates	   calcium-­‐handling	   disturbances	   in	  AF,	  we	  
determined	   whether	   the	   presence	   of	   the	   risk	   variant	   and/or	   AF	   had	   independent	   effects	   on	   the	  
calcium	  homeostasis	  using	  a	  linear	  regression	  model.	  Analysis	  of	  myocytes	  from	  68	  patients	  showed	  
that	   both	   the	   rs13143308	   genotype	   (p=0.004)	   and	   AF	   (p=0.005)	   independently	   increased	   the	   ITI	  
frequency.	   Comparison	   of	   specific	   patient	   groups	   showed	   that	   patients	  with	  No	  AF	   carrying	   a	   risk	  
allele	  had	  a	  5-­‐fold	  higher	   ITI	   frequency	  than	  those	  with	  No	  AF	  and	  normal	  alleles	  at	   rs2200733	  and	  
rs13143308	  (table	  2,	  p<0.001).	  On	  the	  other	  hand	  AF	  increased	  the	  ITI	  frequency	  four-­‐fold	  in	  patients	  
with	   the	  normal	  allele	   (p=0.004).	  Moreover,	   the	  effects	  of	  AF	  and	  4q25	   risk	  variants	  were	  additive	  
with	  the	  ITI	  frequency	  being	  2.3-­‐fold	  higher	  in	  patients	  with	  AF	  and	  a	  risk	  variant	  than	  in	  patients	  with	  
AF	  but	  with	  normal	  variants.	  Analysis	  of	  the	  caffeine	  induced	  NCX	  current	  in	  a	  subset	  of	  53	  patients	  
revealed	  that	  the	  SR	  calcium	  load	  was	  significantly	  modified	  by	  the	  genotype	  (p=0.001)	  but	  not	  by	  AF	  
(p=0.128).	  Comparison	  of	  patient	  groups	   revealed	  a	  significantly	  higher	  SR	  calcium	   load	   in	  patients	  
without	  AF	  that	  carry	  the	  rs13143308T	  risk	  variant.	  There	  were	  no	  differences	  in	  SR	  calcium	  loading	  
or	  in	  NCX-­‐activity	  between	  patients	  with	  AF	  carrying	  normal	  or	  risk	  variants	  (table	  2).	  Analysis	  of	  the	  
L-­‐type	   calcium	   current	   (ICa),	   which	   is	   strongly	   reduced	   in	   patients	   with	   AF,	   revealed	   that	   the	   risk	  
variants	  had	  no	  effect	  on	  ICa	  amplitude	  or	  properties	  in	  patients	  with	  or	  without	  AF	  (supplementary	  
figure	  4).	  
Differential	  effects	  of	  different	  4q25	  risk	  variants	  on	  calcium	  homeostasis	  
To	  determine	  if	  different	  4q25	  risk	  variants	  have	  similar	  effects	  on	  calcium	  homeostasis,	  we	  used	  a	  
linear	  regression	  model	  to	  determine	  the	  effects	  of	  the	  most	  common	  genotype	  combinations	  of	  risk	  
variants	   at	   the	   rs2200733,	   rs13143308	   and	   rs1448818	   loci.	   Taking	   into	   account	   potentially	  
confounding	   effects	   of	   AF,	   this	   analysis	   revealed	   that	   the	   ITI	   frequency	   was	   not	   altered	   by	   the	  
presence	  of	  a	  single	  risk	  variant	  at	  rs1448818.	  By	  contrast,	  the	  ITI	  frequency	  was	  significantly	  higher	  in	  
patients	   carrying	   a	   single	   risk	   variant	   at	   rs13143308	   (p<0.001)	   or	   double	   risk	   at	   rs2200733	   and	  
rs13143308	   (p<0.001,	   Figure	  5A).	   Carriers	   of	   a	   single	   rs13143308	   risk	   variant	   also	  had	   significantly	  
higher	  SR	  calcium	   loading	   than	  patients	  with	  no	  risk	  or	  with	  a	  single	   rs1448818G	  risk	  allele	   (Figure	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5B).	   Analysis	   of	   L-­‐type	   calcium	   current	   (ICa),	   revealed	   no	   significant	   differences	   between	   the	   four	  
most	  common	  genotypes	  (Figure	  5C),	  suggesting	  that	  the	  4q25	  risk	  variants	  are	  not	  targeting	  the	  L-­‐
type	  calcium	  channel	  in	  the	  right	  atrium.	  
4q25	  risk	  variants,	  pitx2c	  deficiency	  and	  calcium	  homeostasis	  	  
Analysis	  of	   the	  mRNA	  levels	  of	  pitx2c,	  which	  has	  been	  proposed	  to	  mediate	  the	  effect	  of	  4q25	  risk	  
variants,	  showed	  that	  pitx2	   levels	  were	  significantly	  reduced	  in	  samples	  from	  patients	  with	  a	  single	  
risk	   variant	   at	   rs13143308	   (p=0.03)	   as	   compared	   to	   pitx2c	   levels	   in	   samples	   from	   patients	   with	   a	  
single	  risk	  variant	  at	  rs1448818	  or	  in	  samples	  from	  patients	  without	  risk	  variants	  at	  any	  of	  the	  three	  
loci	   analyzed	   (Figure	   6A).	   Analysis	   of	  mRNA	   levels	   of	   key	   calcium	   regulatory	   proteins	   in	   the	   same	  
samples	  showed	  higher	  atp2a2	  levels	  and	  the	  atp2a2/pln	  ratio	  in	  samples	  with	  a	  single	  rs13143308T	  
risk	   variant	   (supplementary	   figure	   5),	   which	   may	   contribute	   to	   increase	   SR	   calcium	   loading	   in	  
myocytes	   from	   patients	  with	   this	   genotype.	   No	   significant	   changes	  were	   observed	   in	   ryr2,	   pln,	   or	  
ncx1	  levels	  for	  any	  risk	  variant	  (supplementary	  figure	  5).	  
Theoretically,	   the	   reduced	   pitx2c	   expression	   observed	   in	   our	   patients	   with	   the	   rs13143308T	   risk	  
variant	  could	  underlie	  the	  changes	  in	  calcium	  homeostasis	  observed	  in	  patients	  with	  this	  variant.	  In	  
support	   of	   this	   hypothesis,	   an	   atrial-­‐specific	   conditional	   heterozygous	   mouse	   model	   of	   pitx2c	  
insufficiency	  (in	  which	  pitx2	  levels	  are	  reduced	  by	  75%	  in	  heterozygotes(34)	  revealed	  that	  right	  atrial	  
myocytes	   from	  pitx2fl/-­‐	  mice	   faithfully	   reproduced	  all	   the	  effects	  of	   the	   rs13143308T	   risk	  variant	   in	  
humans	  on	   spontaneous	   calcium	   release	   (figure	  6B),	   calcium	  waves,	   ITI	   frequency,	   SR	   calcium	   load	  
(supplementary	  Figure	  6),	  and	  spontaneous	  electrical	  activity	  both	  at	   rest	   (Figure	  6C-­‐D)	  and	  during	  
stimulation	   (Figure	   6E).	   Afterdepolarizations	   were	   not	   observed	   at	   any	   stimulation	   frequency	  
between	  0.5	  and	  4	  Hz	  in	  any	  of	  four	  Pitx2fl/fl	  mice.	  	  
Of	   notice,	   the	   calcium	   spark	   frequency	  was	   also	   3.9	   fold	   higher	   in	   22	   left	   atrial	  myocytes	   from	   6	  
Pitx2fl/-­‐	   mice	   than	   in	   25	   left	   atrial	   myocytes	   from	   8	   Pitx2fl/fl	   mice	   (52.7±9.2	   vs.	   13.5±3.5	  
sparks/min/1000µm2;	   p<0.001),	   demonstrating	   that	   pitx2	   deficiency	   promote	   spontaneous	   SR	  




This	  study	  is	  the	  first	  to	  show	  that	  human	  atrial	  myocytes	  from	  patients	  with	  the	  rs13143308T	  AF	  risk	  
variant	  at	  chromosome	  4q25	  have	  deficient	  pitx2c	  expression	  and	  an	  abnormally	  high	   incidence	  of	  
both	   calcium	   release-­‐induced	   ITI	   currents	   and	   spontaneous	  membrane	  depolarizations.	   Since	   these	  
electrophysiological	  alterations	  are	  recognized	  hallmarks	  of	  AF(4,	  10),	  the	  fact	  that	  we	  observe	  them	  
even	  in	  patients	  without	  AF	  suggests	  that	  the	  rs13143308T	  variant	  is	  a	  genetic	  risk	  marker	  for	  AF	  that	  
entails	  excessive	  spontaneous	  calcium	  release-­‐induced	  electrical	  activity.	  
Mechanisms	  promoting	  spontaneous	  SR	  calcium	  release	  in	  the	  4q25	  risk	  variant	  rs13143308T	  	  
Confocal	   calcium	   imaging	   in	   human	   atrial	  myocytes	   from	  our	   patients	   revealed	   that	   the	   4q25	   risk	  
variant	  rs13143308T	  promotes	  spontaneous	  calcium	  waves	  as	  a	  result	  of	  an	  increase	  in	  the	  number	  
of	   calcium	   spark	   sites.	   Since	   calcium	   sparks	   are	   produced	   by	   opening	   of	   the	   RyR2,	   a	   high	   open	  
probability	   of	   the	   RyR2	   has	   been	   alluded	   to	   account	   for	   an	   increased	   incidence	   of	   spontaneous	  
calcium	   sparks	   and	   waves	   (35,	   36).	   Mechanistically,	   an	   increased	   RyR2	   opening	   may	   result	   from	  
several	  factors,	  such	  as	  luminal	  calcium	  activation(37-­‐39),	  hyperphosphorylation	  of	  the	  RyR2(5,	  8-­‐10,	  
40),	   and/or	   increased	   SR	   calcium	   loading(7,	   41).	   In	   accordance	   with	   this,	   we	   found	   higher	   RyR2	  
phosphorylation	   at	   ser2808,	   higher	   expression	   of	   the	   SR	   calcium	   pump	   protein	   (SERCA2),	   atp2a2	  
mRNA	   levels	   and	   the	   atp2a2/pln	   ratio,	   as	   well	   as	   higher	   SR	   calcium	   loading	   in	   carriers	   of	   the	  
rs13143308T	  risk	  variant	  that	  were	  free	  of	  AF.	  These	  findings,	  combined	  with	  the	  lack	  of	  concurrent	  
increase	   in	   the	   SR	   calcium	   buffering	   protein	   CSQ-­‐2,	   suggest	   that	   a	   greater	   number	   of	   RyR2	   could	  
reach	   the	   threshold	   for	   spontaneous	   calcium	   release(42)	   and	   consequently,	   lead	   to	   an	   increased	  
calcium	  spark	  frequency.	   	   Interestingly	  the	  increase	  in	  SR	  calcium	  loading	  was	  only	  observed	  in	  risk	  
carriers	  free	  of	  AF.	  This	  suggests	  that	  the	  rs13143308T	  mediated	  increase	  in	  SR	  calcium	  loading	  may	  
precede	  the	  occurrence	  of	  AF	  and	  might	  contribute	  to	  the	  initiation	  of	  the	  arrhythmia.	  In	  support	  of	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this	  assumption,	  a	  higher	  SR	  calcium	  load	  has	  been	  found	  in	  patients	  with	  paroxysmal	  AF(7)	  but	  not	  
in	  patients	  with	  permanent	  AF(4,	  5,	  7,	  8,	  10).	  
The	   4q25	   risk	   variant	   rs13143308T	   as	   a	   genetic	   risk	   marker	   of	   atrial	   fibrillation	   linked	   to	  
spontaneous	  electrical	  activity	  
Analysis	  of	   specific	  4q25	  genotype	  combinations	  at	   the	   loci	   rs2200733,	   rs13143308	  and	   rs1448818	  
revealed	  that	  the	  presence	  of	  a	  risk	  variant	  at	  rs1448818	  coinciding	  with	  normal	  variants	  at	  the	  other	  
loci	  did	  not	  modify	   the	   ITI	   frequency.	  By	  contrast,	  a	   single	   risk	  allele	  at	   rs13143308	  coinciding	  with	  
normal	  variants	  at	  the	  other	  loci	  increased	  the	  ITI	  frequency	  5-­‐fold.	  Assessment	  of	  the	  specific	  effect	  
of	   the	   rs2200733T	   risk	   allele	   is	   complex	   because	   we	   found,	   as	   others(22),	   that	   rs2200733T	   co-­‐
segregates	  with	  rs13143308T.	  Thus,	  genotyping	  for	  the	  rs13143308	  allele	  alone	  would	  be	  sufficient	  
to	  identify	  patients	  at	  risk	  of	  AF	  associated	  with	  excessive	  spontaneous	  calcium	  release.	  
Functionally,	   the	   presence	   of	   a	   single	   rs13143308T	   risk	   variant	   increased	   both	   the	   frequency	   and	  
amplitude	  of	  spontaneous	  membrane	  depolarizations	  (Figure	  1D-­‐F).	  Of	  notice,	  the	  amplitude	  of	  the	  
ITI	   was	   similar	   in	   patients	   with	   and	  without	   the	   risk	   variant	   (Figure	   1A-­‐C).	   Considering	   that	   the	   ITI	  
amplitude	  is	  expected	  to	  reflect	  electrogenic	  Na+-­‐Ca2+	  exchange	  and	  hence	  determine	  the	  amplitude	  
of	   the	   membrane	   depolarization,	   the	   above	   findings	   suggests	   that	   the	   larger	   depolarizations	   in	  
patients	   with	   the	   rs13143308T	   variant	   might	   occur	   because	   the	   risk	   variant	   induce	   a	   concurrent	  
reduction	  in	  repolarizing	  ionic	  currents,	  which	  would	  increase	  the	  depolarization	  produced	  by	  the	  ITI.	  
In	   support	   of	   this	   notion,	   patients	  with	   AF	   present	   a	   reduction	   in	   potassium	   currents	   in	   the	   right	  
atrium	   that	   help	   repolarizing	   the	   myocyte	   and	   stabilize	   the	   resting	   membrane	   potential(43,	   44).	  
Thus,	   the	  present	   findings	  warrant	   future	   studies	   analyzing	   the	   effect	   of	   4q25	   risk	   variants	   on	   the	  
expression	  and	  activity	  of	  potassium	  channels	  stabilizing	  the	  resting	  membrane	  potential.	  
A	   prominent	   reduction	   in	   the	   ICa	   density	   is	   another	   characteristic	   feature	   of	   atrial	   myocytes	   from	  
patients	  with	  AF(5,	  6,	  31).	  However,	  none	  of	  the	  three	  risk	  variants	  examined	  here	  had	  any	  effect	  on	  
the	   amplitude	   or	   properties	   of	   ICa	   in	   patients	   with	   or	   without	   AF;	   suggesting	   no	   role	   for	   L-­‐type	  
channels	  as	  a	  functional	  link	  between	  these	  4q25	  risk	  variants	  and	  AF.	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Pitx2c	  as	  a	  molecular	   link	  promoting	  excessive	   calcium	  homeostasis	   and	  electrical	   activity	   in	   the	  
rs13143308T	  risk	  variant	  
The	  transcription	  factor	  Pitx2c	  plays	  a	  pivotal	  role	  in	  cardiac	  development,	  regulating	  the	  expression	  
of	  proteins	  such	  as	  connexins	  and	  ion	  channels(30)	  whose	  expression	  is	  altered	  in	  patients	  with	  AF;	  
and	  it	  has	  been	  proposed	  as	  a	  molecular	  substrate	  linking	  4q25	  risk	  variants	  and	  atrial	  fibrillation(22).	  
In	  agreement	  with	  previous	  studies,	  which	  failed	  to	  find	  effects	  of	  the	  rs2200733	  or	  rs1448818	  risk	  
alleles	  on	  pitx2c	  levels(28,	  29),	  we	  observed	  pitx2c	  levels	  in	  samples	  from	  patients	  with	  risk	  alleles	  at	  
rs2200733	  or	  rs1448818	  that	  were	  similar	  to	  the	  pitx2c	  levels	  in	  patients	  without	  risk	  alleles	  at	  any	  of	  
the	  three	  loci	  examined.	  However,	  the	  presence	  of	  a	  single	  rs13143308T	  risk	  variant	  was	  associated	  
with	   a	   significant	   reduction	   in	   the	   pitx2c	   level	   (see	   figure	   6A),	   which	   concurred	   with	   significant	  
increases	   in	   SERCA2	   (atp2a2)	   mRNA	   levels	   and	   the	   atp2a2/plb	   ratio,	   supporting	   the	   notion	   that	  
alterations	   in	   the	   SR	   calcium	   homeostasis	   observed	   in	   patients	   with	   the	   rs13143308T	   risk	   variant	  
could	   be	   regulated	   by	   pitx2c.	   Further	   support	   to	   this	   notion	   is	   provided	   by	   the	   results	   from	   a	  
transgenic	  mouse	  model	  with	  conditional	  heterozygous	  atrial-­‐specific	  pitx2c	  deletion,	  which	  faithfully	  
reproduced	   all	   the	   effects	   of	   the	   rs13143308T	   variant	   on	   calcium	   homeostasis	   and	   spontaneous	  
electrical	   activity	   in	   humans	   (see	   figure	   6B-­‐E	   and	   supplementary	   figure	   6).	   Moreover,	   this	   model	  
presents	  alterations	  in	  calcium	  regulatory	  proteins	  compatible	  with	  our	  findings	  in	  humans(34)	  and	  it	  
displays	  features	  associated	  with	  AF	  such	  as	  atrial	  dilation,	  AV-­‐nodal	  block,	  and	  missing	  p-­‐waves(30).	  	  
Study	  limitations	  
Human	   right	   atrial	   samples.	   Due	   to	   ethical	   constrains,	   our	   study	  was	   limited	   to	   the	  use	  of	   human	  
right	  atrial	  specimens	  because	  they	  can	  be	  routinely	  obtained	  at	  the	  time	  of	  right	  atrial	  cannulation	  
during	   the	  majority	  of	   surgical	   cardiac	   interventions	   that	  use	  extracorporeal	   circulatory	   support.	   In	  
contrast,	  tissue	  samples	  from	  the	  left	  atrium	  are	  only	  available	  in	  patients	  undergoing	  interventions	  
that	   require	   opening	   of	   the	   left	   atrium,	   such	   as	  mitral	   valve	   surgery.	   Even	   in	   these	   cases,	   the	   left	  
atrium	   is	  often	  dilated	  and	  affected	   structurally	   and	   this	  has	  been	   reported	   to	  disturb	   the	   calcium	  
homeostasis(45).	  Therefore,	  an	  unbiased	  analysis	  of	  the	  calcium	  homeostasis	  and	  electrical	  activity	  is	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feasible	   in	  human	  right	  atrial	   samples	  but	  much	   less	  so	   in	   left	  atrial	   samples.	  Thus,	  we	  cannot	  rule	  
out	   that	  some	  of	  our	   findings	  are	  specific	   to	   the	  right	  atrium.	  Underlying	  cardiovascular	  disease	  or	  
pharmacological	   treatments	   could	   also	   influence	   our	   results,	   but	   there	   were	   no	   significant	  
differences	   in	  the	  incidence	  of	  concurrent	  diseases	  or	   in	  the	  drug	  prescription	  among	  patients	  with	  
and	  without	  4q25	  risk	  variants	  (see	  Table	  1).	  
Functional	  effect	  of	  Pitx2c	  in	  right	  atrial	  samples.	  It	  is	  generally	  acknowledged	  that	  pitx2c	  expression	  
levels	  are	  low	  in	  the	  right	  atrium,	  reaching	  levels	  that	  approach	  the	  detection	  limit	  and	  can	  give	  rise	  
to	   considerable	   variation	   in	   pitx2c	   levels(30).	   This	   in	   turn	   has	   raised	   doubts	   about	   the	   functional	  
relevance	  of	  Pitx2c	   in	   the	  right	  atrium	  as	  compared	  to	   the	   left	  atrium	  where	  pitx2c	   levels	  are	  100-­‐
1000	   fold	   higher(28,	   30).	   Moreover,	   several	   studies	   have	   failed	   to	   demonstrate	   consistent	   links	  
between	  4q25,	  pitx2c	  expression,	  and	  AF(28-­‐31),	  even	  in	  left	  atrial	  samples.	  Our	  findings	  are	  subject	  
to	  the	  same	  limitations	  and,	  even	  though	  the	  effect	  of	  the	  rs13143308T	  variant	  on	  pitx2c	  expression	  
has	  not	  been	  examined	  previously,	  we	  cannot	  rule	  out	  that	  the	  observed	  depression	  of	  pitx2c	  levels	  
for	   this	   variant	   and	   the	   concurrent	   changes	   in	   calcium	   regulatory	   proteins	   could	   be	   secondary	   to	  
modulation	  of	  another	  transcription	  factor(46).	  On	  the	  other	  hand,	  atrial-­‐specific	  Pitx2c	  deficiency	  in	  
our	  transgenic	  mouse	  model	  has	  previously	  been	  reported	  to	  produce	  atrial	  dilation	  in	  both	  right	  and	  
left	   atria(30).	   Furthermore,	   in	   the	   present	   study	   right	   atrial	   myocytes	   from	   the	   pitx2cfl/-­‐	   mice	  
faithfully	  reproduced	  observations	   in	  the	  human	  right	  atrial	  samples	  and	  pitx2c	  deficiency	  had	  very	  
similar	   effects	   on	   the	   SR	   calcium	   homeostasis	   and	   spontaneous	   electrical	   activity	   in	   right	   and	   left	  
atrial	   pitx2cfl/-­‐	   myocytes,	   demonstrating	   that	   Pitx2c	   deficiency	   has	   functionally	   relevant	   effects	   on	  
calcium	  homeostasis	  in	  the	  right	  atrium	  and	  that	  these	  are	  similar	  to	  the	  effects	  observed	  in	  the	  left	  
atrium.	  
Clinical	  implications	  	  
Our	   study	   identifies	   the	   4q25	   rs13143308T	   risk	   allele	   as	   a	   genetic	   marker	   for	   AF	   risk	   linked	   to	  
excessive	   calcium	   release	   and	   spontaneous	   electrical	   activity.	   Clinically,	   this	   should	   provide	   novel	  
means	  for	  1)	  Identification	  of	  patients	  with	  AF	  or	  at	  risk	  of	  it,	  in	  whom	  the	  arrhythmia	  is	  specifically	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linked	   to	   defective	   calcium	   homeostasis	   and	   2)	   Improvement	   of	   stratification	   and	   treatment	   of	  
patients	  with	  AF.	  Specifically,	  the	  abnormally	  high	  incidence	  of	  calcium	  release	  observed	  in	  patients	  
with	  the	  rs13143308T	  variant	  settles	  the	  bases	  for	  testing	  whether	  current	  or	  novel	  pharmacological	  
therapies	   targeting	   SR	   calcium	   release	   are	   more	   efficient	   in	   preventing	   AF	   in	   patients	   with	   this	  
variant	  than	  in	  patients	  with	  normal	  rs13143308G	  alleles.	  
Conclusions	  
In	   conclusion,	   our	   results	   identify	   the	   rs13143308T	   risk	   variant	   on	   chromosome	   4q25	   as	   potential	  
biomarker	  for	  AF	  linked	  to	  arrhythmogenic	  calcium	  release	  and	  a	  new	  key	  to	  understand	  the	  complex	  




Human	   biological	   samples,	   SNP	   genotyping,	   and	   atrial	   myocyte	   experimentation.	  A	   total	   of	   543	  
blood	   samples	   were	   genotyped	   for	   the	   presence	   of	   the	   normal	   4q25	   variants	   rs2200733C,	  
rs13143308G	   and	   rs1448818T	   or	   for	   the	   corresponding	   AF	   risk	   variants	   rs2200733T,	   rs13143308T	  
and	   rs1448818G.	   Right	   atrial	   myocardial	   samples	   were	   collected	   from	   280	   genotyped	   patients	  
undergoing	   cardiac	   surgery	   with	   extracorporeal	   circulation.	   Each	   patient	   gave	   written	   consent	   to	  
obtain	  blood	  and	  tissue	  samples.	  The	  latter	  would	  otherwise	  have	  been	  discarded	  during	  the	  surgical	  
intervention.	  The	  study	  was	  approved	  by	  the	  Ethics	  Committees	  of	   the	  Spanish	  National	  DNA	  Bank	  
(BNADN,	  Salamanca),	  Hospital	  de	  la	  Santa	  Creu	  i	  Sant	  Pau	  (Barcelona)	  and	  of	  the	  University	  of	  Jaén;	  
and	  the	  investigation	  conforms	  to	  the	  principles	  outlined	  in	  the	  Declaration	  of	  Helsinki.	  	  
Human	  atrial	  myocyte	   isolation.	  Samples	  were	  excised	  from	  the	  right	  atrial	  appendage	  of	  patients	  
undergoing	   cardiac	   surgery	   with	   extracorporeal	   circulation	   (mostly	   bypass	   and/or	   valve	  
replacements).	   Samples	   were	   stored	   immediately	   in	   cold	   oxygenated	   Tyrode	   solution	   and	   snap-­‐
frozen	  or	  used	  for	  myocyte	  isolation	  within	  5-­‐10	  min	  after	  excision.	  For	  myocyte	  isolation,	  the	  sample	  
was	   cut	   into	   small	   fragments	   and	   digested	   in	   a	   calcium-­‐free	   Tyrode	   solution	   with	   1.2mg/ml	  
collagenase	   (Worthington	   type	   2,	   255	   or	   298	   u/mg),	   0.45	  mg/ml	   proteinase	   (Sigma	   type	   XXIV,	   11	  
u/mg	  solid),	  and	  2	  mg/ml	  bovine	  fatty	  acid-­‐free	  albumin.	  After	  30	  minutes,	  cells	  were	  liberated	  from	  
the	  tissue	  fragments	   in	  Ca2+-­‐free	  solution	  by	  gentle	  agitation	  with	  a	  Pasteur	  pipette.	  The	  remaining	  
tissue	  was	  digested	  for	  3x15	  minutes	  in	  calcium	  free	  solution	  containing	  0.7	  mg/ml	  collagenase.	  Only	  
elongated	  cells	  with	  clear	  cross	  striations	  and	  without	  abnormal	  granulation	  were	  used.	  
Clinical	   characterization	   and	   SNP	   Genotyping.	   Clinical	   information	   relevant	   to	   this	   study	   and	  
included	   in	   table	   1	  was	   collected	   from	   the	   clinical	   records	   by	   a	   clinician.	  Medication	   refers	   to	   the	  
patient	   medication	   prescribed	   before	   the	   surgical	   intervention.	   Patients	   without	   any	   incidents	   of	  
atrial	   fibrillation	   (AF)	   in	   the	   clinical	   record	  were	   considered	   free	   of	   the	   arrhythmia.	   Patients	  were	  
classified	   as	   having	   paroxysmal	   or	   chronic	  AF	   according	   to	   the	   information	   available	   in	   the	   clinical	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record.	   Chronic	   AF	   included	   patients	   having	   persistent	   or	   long-­‐term	   persistent	   AF.	   To	   reduce	  
fractioning	  of	  the	  data,	  patients	  with	  paroxysmal	  and	  chronic	  AF	  were	  pooled	  into	  a	  single	  group	  of	  
AF	  patients.	   This	   grouping	  was	  done	  because	  unpublished	  data	   from	  our	   laboratory	  and	  published	  
data(7)	  show	  that	  spontaneous	  calcium	  release	  is	  already	  elevated	  in	  patients	  with	  paroxysmal	  AF.	  	  	  
SNP	   genotyping.	   Polymerase	   chain	   reaction	   amplification	   of	   the	   SNPs	   rs2200733,	   rs13143308	   and	  
rs1448818	  were	   carried	   out	   using	   flanking	   oligonucleotides	   as	   outlined	   in	   Supplementary	   Table	   1,	  
followed	  by	  direct	   sequencing.	  Genomic	  DNA	  samples	   from	  174	  patients	  with	  AF	  and	  369	  patients	  
with	  no	  reported	  episodes	  of	  AF	  were	  included	  and	  analyzed.	  Samples	  from	  the	  174	  patients	  with	  AF	  
were	   collected	   as	   follows:	   75	   at	   the	   Spanish	   National	   DNA	   Bank	   (BNADN,	   Salamanca),	   68	   at	   the	  
Cardiology	  Service	  at	  Hospital	  de	  la	  Santa	  Creu	  i	  Sant	  Pau,	  Barcelona,	  and	  31	  at	  the	  Cardiology	  Unit	  of	  
the	  Hospital	  Regional	  Ciudad	  de	  Jaén.	  Samples	  from	  the	  369	  patients	  free	  of	  FA	  were	  obtained	  from	  
the	  Spanish	  National	  DNA	  Bank	  (BNADN,	  Salamanca)	  in	  157	  cases	  and	  from	  Hospital	  de	  la	  Santa	  Creu	  
i	   Sant	   Pau	   (Barcelona)	   in	   212	   cases.	   For	   all	   atrial	   samples	   used	   for	   electrophysiological	   and/or	  
molecular	   biological	   studies,	   genotyping	   was	   done	   for	   batches	   of	   samples	   after	   experiments	   had	  
been	  performed	  and	  analyzed.	  
Transgenic	  mouse	  model	   and	  myocyte	   isolation.	   The	  Pitx2	   floxed	  and	  NppaCre	   transgenic	  mouse	  
lines	  have	  been	  described	  previously(30,	  34).	  Wild	  type	  Cre-­‐	  controls	  (NppaCre-­‐Pitx2fl/fl)	  and	  atrial-­‐
specific	   heterozygous	   (NppaCre+Pitx2fl/-­‐)	   mice	   were	   used	   in	   this	   study.	   Cardiomyocytes	   were	  
isolated	   from	   3-­‐6	  months-­‐old	   NppaCre-­‐Pitx2fl/fl	   and	  NppaCre+Pitx2+/-­‐	  mice(2).	   Briefly,	  mice	  were	  
anesthetized	   (I.P.	  medetomidine	  1	  mg/kg	  and	  ketamine	  75	  mg/kg)	  and	  heparinized	   (I.P.	  25	   IU/ml).	  
Twenty	  minutes	  later,	  after	  cervical	  dislocation,	  the	  heart	  was	  quickly	  excised	  and	  arrested	  in	  ice-­‐cold	  
Ca2+-­‐free	   Tyrode	   solution.	   Hearts	   were	   then	   Langendorff	   perfused	   with	   an	   enzymatic	   solution	  
(collagenase,	  proteinase	  and	  BSA)	  of	  Ca2+-­‐free	  Tyrode	  during	  approximately	  8	  min.	  Afterwards,	  the	  
right	   atrial	   chamber	   was	   dissected	   and	   cut	   into	   small	   pieces,	   washed	   twice	   in	   Ca2+-­‐free	   Tyrode	  
solution	  by	  gentle	  agitation,	  and	  transferred	  back	  into	  a	  fresh	  enzymatic	  solution	  for	  approximately	  8	  
min.	  This	  process	  was	  repeated	  several	  times	  until	  an	  adequate	  number	  of	  elongated	  atrial	  myocytes	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with	  clear	  striations	  had	  been	  released.	  Subsequently	  cells	  were	  pooled,	  centrifuged	  for	  5	  min	  at	  500	  
rpm,	   resuspended	   in	   Tyrode	   solution,	   and	   the	   [Ca2+]	   was	   gradually	   increased	   to	   1	   mM.	   The	  
experimentation	   with	   mouse	   atrial	   myocytes	   conforms	   to	   the	   Guide	   for	   the	   Care	   and	   Use	   of	  
Laboratory	  Animals,	  and	  was	  approved	  by	  the	  Bioethical	  Committee	  at	  Hospital	  de	  Santa	  Creu	  i	  Sant	  
Pau.	  
Western	   blot	   and	   immunofluorescent	   labelling.	   Approximately	   20	   mg	   of	   right	   atrial	   sample	   was	  
pulverized	  in	  liquid	  nitrogen	  and	  homogenized	  in	  200	  µl	  of	  ice-­‐cold	  lysis	  buffer	  containing	  (in	  mM):	  50	  
HEPES,	  100	  NaCl,	  2.5	  EGTA,	  10	  glycerol-­‐2-­‐phosphate	  1	  DTT	  supplemented	  with	  a	  cocktail	  of	  protease	  
inhibitors	   (Roche)	   and	  with	   0.1%	   (v/v)	   Tween	   20	   and	   10%	   (v/v)	   glycerol	   at	   pH=7.4.	   Proteins	  were	  
separated	   by	   SDS-­‐PAGE	   (10%	   acrylamide:bisacrylamide)	   and	   electrotransferred	   onto	   Immobilon	  
polyvinylidene	   diflouride	   membranes	   (Millipore).	   Membranes	   were	   incubated	   with	   primary	   and	  
secondary	  antibodies	  diluted	  in	  5%	  non-­‐fat	  dry	  milk.	  Antibodies	  against	  SERCA2	  (#9580,	  Cell	  Signaling	  
Technology),	   CSQ-­‐2	   (ab3516,	   Abcam)	   and	   NCX1	   (ab135735,	   Abcam)	   were	   used.	   Detection	   was	  
performed	   using	   the	   appropriate	   horseradish	   peroxidase-­‐labeled	   IgG	   and	   the	   SupersignalTM	  
detection	  system	  (Supersignal	  West	  DuraTM,	  Pierce).	  Molecular-­‐mass	  standards	  (Bioline)	  were	  used	  
to	   estimate	   protein	   size	   and	   glyceraldehyde-­‐3-­‐phosphate	   dehydrogenase	   (GAPDH;	   MAB374,	  
Millipore)	   was	   used	   as	   a	   loading	   control.	   Immunoblots	   were	   digitized	   (GS-­‐800	   Calibrated	  
Densitometer;	  Bio-­‐Rad)	  and	  analyzed	  with	  the	  Quantity	  One	  4.6.3	  software	  (Bio-­‐Rad).	  
Isolated	   myocytes	   were	   fixed	   with	   paraformaldehyde	   4%	   for	   5	   minutes	   at	   room	   temperature.	  
Subsequently,	  cells	  were	  first	   incubated	  with	  PBS	  /	  Glycine	  0.1	  M	  during	  10	  minutes	  and	  then	  with	  
PBS	   /	   Triton	   X-­‐100	   0.2%	   for	   at	   least	   30	  minutes	   to	   permeabilize	   the	   cells.	   Non-­‐specific	   sites	  were	  
blocked	   with	   PBS	   /	   Tween	   20,	   0.2%	   and	   Horse	   serum,	   10%	   for	   30	   minutes.	   Myocytes	   were	  
inmunofluorescently	   labeled	   with	   the	   primary	   antibodies	   mouse	   anti-­‐RyR2	   (C3-­‐33	   NR07,	   1:1000;	  
calbiochem)	  and	   rabbit	   anti-­‐ser2808-­‐P	   (1:600,	  A010-­‐30,	  Badrilla).	  After	   labeling,	   cells	  were	  washed	  
again	   and	   stored	   with	   PBS-­‐Azide,	   0.2	   %	   at	   4ºC	   until	   visualization.	   The	   secondary	   antibodies	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AlexaFluor	   488	   anti-­‐mouse	   and	   AlexaFluor	   594	   anti-­‐rabbit	   were	   diluted	   1:1000.	   Images	   were	  
acquired	  with	  a	  confocal	  microscope	  (Leica	  AOBS	  SP5)	  using	  a	  63x	  glycerol	  immersion	  objective.	  	  	  	  	  
mRNA	   extraction,	   reverse	   transcription	   and	   real	   time	   PCR.	   RNA	  was	  obtained	   from	  human	  atrial	  
samples	   using	   RNeasy	   Mini	   kit	   (Qiagen)	   and	   the	   RNA	   was	   treated	   with	   DNase	   using	   Rnase-­‐Free	  
DNase	   Set	   (Qiagen).	   Subsequently,	   reverse	   transcription	   was	   carried	   out	   using	   1	   µg	   of	   RNA	   and	  
QuantiTect	  Reverse	  Transcription	  kit	   (Qiagen),	  and	  1	  µL	  of	   the	  reverse	  transcriptase	  was	  used	  with	  
SsoFast	   EvaGreeen	   Supermix	   (Bio-­‐Rad)	   for	   real	   time	   PCR,	  which	  was	   done	   using	   a	   CFX384	   system	  
from	   Bio-­‐Rad.	   Quantification	   of	   the	   PCR	   was	   done	   using	   the	   2-­‐∆∆Ct	   method	   as	   previously	  
described(2).	  
The	  following	  primer	  sequences	  were	  used	  for	  Pitx2c:	  
Pitx2c:	   	   5´CTTTCCGTCTCCGGACTTTT3´	  
5´CGCGACGCTCTACTAGTCCT3´	  
Pitx2c	  expression	  was	  normalized	  to	  PPIA	  GAPDH,	  or	  NKX2.5	  using	  the	  following	  primer	  sequences:	  
PPIA:	   	   5´TCGAGTTGTCCACAGTCAGC3´	  
5´TTCATCTGCACTGCCAAGAC3´	  
GAPDH:	   5´AGCCACATCGCTCAGACACA3´	  
5´AACCATGTAGTTGAGGTCAAT3´	  
NKX2.5:	   5´CTTCACCGGCCAAGTGTG3´	  
	   	   5´GCCTCTGTCTTCTCCAGCTC3´	  
Linear	   regression	   analysis	   revealed	   that	   Pitx2c	   expression	   levels	   were	   highly	   correlated	   for	   all	  
combinations	  of	  primer	  pairs.	  	  GADPH	  vs.	  PPIA:	  R2=0,752,	  n=50	  p<0.001;	  NKX2.5	  vs.	  PPIA:	  R2=0.815,	  
n=17,	  p<0.001;	  NKX2.5	  vs	  GADPH:	  R2=0.815,	  n=17,	  p<0.001.	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Patch-­‐clamp	   technique.	   ICa	   was	   elicited	   by	   a	   200	  ms	   depolarization	   to	   0	   mV	   and	   spontaneous	   ITI	  
currents	  were	  measured	  at	  holding	  potentials	  of	  -­‐80	  or	  -­‐50	  mV	  using	  whole	  cell	  voltage-­‐clamp	  in	  the	  
perforated	   patch	   configuration	   with	   a	   HEKA	   EPC-­‐10	   amplifier	   (HEKA	   Elektronik	   Dr.	   Schultze,	  
Lambrecht/Pfalz,	  Germany).	  Na-­‐currents	  were	  eliminated	  by	  a	  50	  ms	  depolarization	  to	  -­‐50	  mV	  prior	  
to	  activation	  of	  ICa.	  Series	  resistance	  compensation	  was	  not	  performed.	  Access	  resistance	  was	  9±0.5	  
MΩ.	  The	  extracellular	  solution	  contained	   (in	  mM):	  NaCl	  127,	  TEA	  5,	  HEPES	  10,	  NaHCO3	  4,	  NaH2PO4	  
0.33,	   glucose	   10,	   pyruvic	   acid	   5,	   CaCl2	   2,	  MgCl2	   1.8,	   (pH	   =	   7.4).	   The	   pipette	   solution	   contained	   (in	  
mM):	  aspartic	  acid	  109,	  CsCl	  47,	  Mg2ATP	  3,	  MgCl2	  1,	  Na2phosphocreatine	  5,	  Li2GTP	  0.42,	  HEPES	  10	  
(pH	  =	  7.2	  with	  CsOH)	  and	  250	  µg/ml	  amphotericin	  B.	  Experiments	  began	  when	  the	  series	  resistance	  
did	  not	  decrease	  further,	  and	  cells	  were	  discarded	  if	  it	  was	  larger	  than	  6	  times	  the	  pipette	  resistance.	  
The	   ICa	   amplitude	   was	   determined	   as	   the	   difference	   between	   the	   peak	   inward	   current	   and	   the	  
current	   at	   the	   end	  of	   the	  depolarization,	   and	   the	   current-­‐voltage	   relationship	   for	   ICa	  was	  obtained	  
using	   test	   potentials	   between	   -­‐40	   and	   +50	   mV.	   Voltage-­‐dependent	   inactivation	   was	   determined	  
using	  pre-­‐pulses	  between	  -­‐40	  and	  0	  mV	  followed	  by	  a	  second	  200	  ms	  depolarization	  to	  +10	  mV,	  and	  
data	  were	   fit	  with	  Boltzmann	  equation	  to	  determine	  the	  voltage	   for	  half-­‐maximal	   inactivation.	  The	  
time	   constants	   for	   ICa	   inactivation	  were	   determined	   from	   a	   double	   exponential	   fit	   of	   the	   decaying	  
phase	  of	  ICa.	  
The	   SR	   calcium	   load	   was	   determined	   from	   the	   charge	   carried	   by	   the	   current	   elicited	   by	   rapid	  
exposure	  to	  10	  mM	  caffeine	  for	  5	  to	  10	  s.	  The	  charge	  was	  converted	  to	  amoles	  (10-­‐18	  mol)	  of	  calcium	  
released	  from	  the	  SR,	  assuming	  a	  stoichiometry	  of	  3Na+:1Ca2+	  for	  the	  NCX	  and	  normalized	  to	  the	  cell	  
capacitance.	   Experimental	   protocols	   were	   linked	   and	   executed	   sequentially.	   Erroneous	  
measurement(s)	   were	   eliminated,	   giving	   rise	   to	   variations	   in	   the	   total	   number	   of	   experiments	   for	  
different	  currents.	  Most	  of	  these	  cases	  occurred	  because	  exposure	  of	  myocytes	  to	  caffeine	  produced	  
sudden	  increases	  in	  the	  leakage	  current	  or	  irreversible	  cell	  contracture	  in	  some	  myocytes.	  Similarly,	  
in	  myocytes	  used	  for	  current	  clamp	  experiments,	  the	  ITI	  frequency,	  but	  not	  ICa	  was	  determined	  using	  
the	  voltage-­‐clamp	  configuration	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Membrane	   potentials	  were	  measured	   in	   the	   current-­‐clamp	   configuration	   using	   K+-­‐containing	   intra	  
and	   extracellular	   media.	   The	   bath	   solution	   contained	   (in	   mM):	   NaCl	   136,	   KCl	   4,	   NaH2PO4	   0.33,	  
NaHCO3	  4,	  CaCl2	  2,	  MgCl2	  1.6,	  HEPES	  10,	  Glucose	  5,	  pyruvic	  acid	  5,	   (pH	  =	  7.4).	  The	  pipette	  solution	  
contained	  (in	  mM):	  aspartic	  acid	  109,	  KCl	  47,	  Mg2ATP	  3,	  MgCl2	  1,	  Na2phosphocreatine	  5,	  Li2GTP	  0.42,	  
HEPES	  10	  (pH	  =	  7.2	  with	  KOH)	  and	  250	  µg/ml	  amphotericin	  B.	  The	  holding	  current	  was	  varied	  in	  order	  
to	   assess	   the	   amplitude	   and	   frequency	   of	   spontaneous	   membrane	   depolarizations	   at	   different	  
resting	  membrane	  potentials.	  Results	  were	  pooled	  in	  10	  mV	  intervals:	  -­‐80mV	  represents	  the	  mean	  of	  
events	  recorded	  at	  potentials	  between	   -­‐85	  and	  -­‐76mV;	   -­‐70mV:	  the	  mean	  between	  -­‐75	  and	  -­‐66	  mV	  
and	  -­‐60mV:	  the	  mean	  between	  -­‐65	  and	  -­‐56mV.	  
Confocal	  calcium	  imaging.	  To	  visualize	  changes	  in	  the	  intracellular	  calcium	  concentration,	  myocytes	  
were	  loaded	  with	  2.5	  µM	  fluo-­‐4	  AM.	  Confocal	  calcium	  images	  (512x140	  pixels)	  were	  recorded	  at	  90	  
Hz,	  using	  a	  resonance-­‐scanning	  confocal	  microscope	  with	  a	  63x	  glycerol-­‐immersion	  objective	  (Leica	  
SP5	  AOBS,	  Wetzlar,	  Germany).	  Fluo-­‐4	  was	  excited	  at	  488	  nm	  and	  emission	  was	  measured	  between	  
500	   and	   650nm	  with	   a	   Leica	   Hybrid	   Detector.	   Laser	   power	   was	   set	   to	   20%	   of	   100	  mW	   and	   then	  
attenuated	  to	  4%.	  Experiments	  were	  performed	  at	  room	  temperature.	  	  
To	   detect	   calcium	   sparks,	   a	  wavelet-­‐based	  detection	  method	  was	   applied	   to	   the	  normalized	   time-­‐
dependent	   fluorescence	   signal	   zi(t)	   at	   every	   pixel	   in	   order	   to	   detect	   candidates	   for	   Ca2+	   release	  
events.	  	  More	  specifically,	  Gaussian	  wavelet	  of	  order	  2	  with	  scales	  from	  5	  to	  10	  were	  used	  in	  order	  to	  
enhance	  Ca2+	  release	  events	  with	  a	  duration	  of	  20	  to	  300	  ms.	  Candidate	  event	  regions	  were	  detected	  
by	  thresholding	  the	  wavelet	  signals	  at	  3.5	  σ.	  The	  noise	  variance	  of	  the	  wavelet	  signal	  σ	  was	  robustly	  
estimated	  using	  the	  median	  absolute	  deviation	  of	  the	  fluorescence	  signal	  of	  a	  pixel	  at	  the	  center	  of	  
the	  cell.	  Subsequently,	  spark	  candidates	  were	  filtered	  based	  on	  a	  relative	  intensity	  threshold	  of	  0.4,	  a	  
full	  duration	  at	  half	  maximum	  between	  10	  and	  150	  ms,	  a	  spark	  decay	  constant	  between	  15	  to	  150	  ms	  
and	  a	  minimal	  R2	   for	  the	  exponential	   fit	  of	  the	  decay	  of	  0.5.	  To	  eliminate	  sparks	  occurring	  within	  a	  
calcium	   wave,	   events	   with	   an	   elevated	   baseline	   (1.5x	   or	   higher)	   were	   eliminated.	   The	   program	  
allowed	  visual	  inspection	  of	  the	  calcium	  signal	  in	  consecutive	  images	  and	  the	  spatial	  location	  of	  each	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detected	   spark	  was	   indicated	   in	   the	   corresponding	   images	   in	   order	   to	  manually	   validate	   or	   reject	  
doubtful	   events.	   The	  program	  also	   allowed	  merging	  of	   consecutive	   recordings	   from	   the	   same	   cell.	  
After	   supervised	   validation	   and	  merging,	   sparks	   that	   coincided	   spatially	   (within	   a	   radius	   of	   2	   µm)	  
were	  pooled	  into	  a	  common	  spark	  site	  and	  calcium	  traces	  were	  generated	  for	  each	  spark	  site.	  Each	  
spark	   was	   characterized	   by	   its	   amplitude,	   its	   duration	   characterized	   as	   the	   Full	   Duration	   at	   Half	  
Maximum	  (FDHM)	  and	  its	  width	  characterized	  as	  the	  Full	  Width	  at	  Half	  Maximun	  (FWHM).	  The	  spark	  
frequency	  was	   calculated	   as	   the	  number	   of	   sparks/cell/s	   or	   normalized	   to	   the	   cell	   area	  within	   the	  
confocal	   plane	   and	   expressed	   as	   sparks/µm2/s.	   Additionally,	   the	   number	   of	   spark	   sites	   were	  
expressed	   as	   sites/cell	   or	   normalized	   to	   the	   cell	   area	   and	   given	   as	   sites/µm2.	   The	   average	   spark	  
frequency	  per	  site	  was	  given	  as	  sparks/site/s.	  
Statistics	   Electrophysiological	   and	   molecular	   biological	   analysis	   of	   human	   atrial	   samples	   was	  
performed	  without	  knowledge	  about	  clinical	  data	  or	  genotypes	  and	  clinicians	  gathering	   the	  clinical	  
data	  did	  not	  know	  the	  experimental	  results.	  Data	  sets	  were	  analyzed	  with	  SPSS	  statistical	  software.	  
Unless	   otherwise	   stated,	   values	   were	   averaged	   for	   each	   patient.	   Mean	   values	   are	   indicated	   with	  
horizontal	   bars	   in	   dot	   plots	   or	   given	   as	   mean±s.e.m.	   as	   indicated.	   Statistical	   significance	   was	  
evaluated	   using	   Fisher’s	   exact	   test	   for	   categorical	   data.	   Student’s	   t-­‐test	   was	   used	   for	   paired	   or	  
unpaired	  comparisons,	  and	  ANOVA	  or	  a	  linear	  regression	  model	  was	  used	  for	  comparison	  of	  multiple	  
effects	  as	   indicated.	  For	   the	   statistical	  analysis	  of	   the	  effects	  of	   the	  different	  genotypes	  containing	  
the	   three	  SNPs,	  we	  used	  a	   linear	   regression	  model	   taking	   into	  account	   the	  effects	  of	   the	  different	  
genotypes,	  the	  presence	  of	  AF,	  and	  whether	  the	  patients	  were	  undergoing	  mitral	  valve	  replacement.	  
Based	   on	   the	   linear	   regression	   model,	   the	   effect	   of	   AF	   and	   the	   most	   common	   genotypes	   was	  
estimated	  and	  given	  as	  mean±s.e.m.	  Statistically	  significant	  effects	  are	  indicated	  with	  p-­‐values	  or	  *:	  
p<0.05,	  **:	  p<0.01;	  ***:	  p<0.001.	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Figure	  1.	  The	  risk	  variant	  rs13143308T	  increases	  spontaneous	  electrical	  activity.	  	  
A	  Spontaneous	  ITI	  currents	  in	  patients	  with	  a	  normal	  or	  a	  risk	  variant	  at	  rs13143308.	  B	  ITI	  frequency	  in	  
myocytes	  with	  (risk)	  or	  without	  a	  risk	  variant	  (normal).	  C	  ITI	  amplitude	  in	  the	  myocytes	  from	  panel	  B.	  
D	  Membrane	  potential	  recordings	  at	  -­‐80	  mV	  in	  myocytes	  from	  a	  patient	  with	  normal	  and	  one	  with	  a	  
risk	   variant.	   E	   Frequency	   of	   spontaneous	   membrane	   depolarizations	   at	   -­‐80	   mV	   in	   patients	   with	  
normal	  and	  risk	  variants.	  F	  Amplitude	  of	  the	  depolarizations	  in	  the	  myocytes	  from	  panel	  E.	  P-­‐values	  
from	  unpaired	  t-­‐tests	  are	  given	  above	  and	  the	  number	  of	  patients	  in	  parentheses.	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Figure	  2.	  The	  rs13143308T	  risk	  variant	  increases	  the	  calcium	  spark	  density.	  	  	  
A	   Longitudinal	   plane	   of	   a	   human	   atrial	   myocyte	   from	   a	   patient	   with	   a	   4q25	   risk	   variant,	   with	  
indication	   of	   four	   spark	   sites	   on	   the	   left	   (colored	   rectangles).	   Calcium	   signals	   are	   shown	   for	   each	  
spark	  site	  on	  the	  right.	  Insets	  show	  calcium	  signals	  for	  individual	  sparks.	  B	  Spark	  frequency.	  C	  Spark	  
sites	   per	   cell.	   D	   Spark	   firing	   frequency.	   P-­‐values	   from	   unpaired	   t-­‐tests	   are	   given	   above	   and	   the	  
number	  of	  patients	  in	  parentheses.	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Figure	  3.	  Calcium	  spark	  properties	  do	  not	  depend	  on	  the	  genotype	  at	  rs13143308.	  	  	  
A	  Ca2+	  transient	  from	  a	  single	  spark	  site.	  Consecutive	  8	  x	  8	  µm	  images	  of	  the	  calcium	  spark	  are	  shown	  
below	   the	   Ca2+	   transient	   during	   its	   rise	   and	   decay	   (white	   window	   area).	  B	   Enlarged	   image	   of	   the	  
calcium	   spark	   in	   panel	   A,	   recorded	   at	   its	   maximal	   amplitude.	   The	   profile	   of	   the	   calcium	   spark	   is	  
shown	  on	  the	  right	  for	  each	  of	  the	  four	  colored	  axes	  outlined	  in	  the	  image	  on	  the	  left.	  The	  width	  of	  
the	  calcium	  spark	  at	  half	  maximum	  (FWHM)	  was	  calculated	  as	  the	  average	  FWHM	  of	  the	  four	  axes	  C	  
Calcium	  spark	  amplitude.	  D	  Calcium	  spark	  duration	  at	  half	  maximum	  (FDHM).	  E	  FWHM.	  Values	  are	  
from	  the	  same	  myocytes	  as	  in	  figure	  2.	  P-­‐values	  for	  unpaired	  t-­‐tests	  are	  given	  above	  and	  the	  number	  























































































Figure	  4.	  	  SR	  calcium	  loading	  and	  SERCA2	  expression	  is	  increased	  in	  patients	  with	  the	  rs13143308T	  
risk	  variant.	  
A	  Visualization	  of	  total	  RyR2	  clusters	  (green)	  and	  ser2808	  phosphorylated	  clusters	  (red)	   in	  a	  human	  
atrial	   myocyte.	   The	   degree	   of	   ser2808	   phosphorylation	   was	   estimated	   as	   the	   ratio	   of	   the	  
ser2808/RyR2	  intensity	  for	  each	  RyR2	  cluster	  (right).	  B	  Caffeine-­‐induced	  currents	  (top)	  and	  their	  time	  
integral	  (bottom)	  for	  a	  normal	  and	  a	  risk	  variant.	  The	  SR	  calcium	  load	  is	  shown	  on	  the	  right.	  C	  Left:	  
Relationship	  between	  the	  activity	  of	  the	  NCX	  and	  the	  calcium	  available	  for	  extrusion	  for	  a	  normal	  and	  
a	  risk	  variant.	  The	  slopes	  of	  the	  relationships	  are	  shown	  on	  the	  right.	  D	  Immunoblots	  of	  SERCA2,	  CSQ-­‐
2,	   NCX-­‐1	   and	   GADPH	   in	   right	   atrial	   samples	   from	   patients	   with	   normal	   or	   risk	   variants	   at	   4q25.	  
GADPH	   served	   as	   reference.	  Mean	   SERCA2,	   CSQ-­‐2	   and	  NCX-­‐1	   expression	   levels	   are	   shown	   on	   the	  
right.	   Values	   were	   normalized	   to	   the	   mean	   expression	   level	   in	   the	   normal	   variant.	   P-­‐values	   for	  






































































































Figure	  5.	  Effects	  of	  different	  4q25	  risk	  variants	  on	  calcium	  homeostasis.	  
A	   ITI	   frequency	  in	  the	  four	  common	  combination	  of	  4q25	  polymorphisms	  at	  rs2200733,	  rs13143308	  
and	  rs1448818	  indicated	  below	  bars.	  B	  Corresponding	  effects	  of	  these	  genotypes	  on	  SR	  calcium	  load.	  
C	   Effect	   of	   the	   same	   genotypes	   on	   ICa	   amplitude.	   The	   number	   of	   patients	   is	   given	   for	   each	   bar.	  
Statistical	   significance	   was	   determined	   using	   a	   linear	   regression	   model	   taking	   into	   account	   the	  
genotype	  of	  all	  samples	  analyzed.	  *:p<0.05;	  **:p<0.01;	  ***:p<0.001.	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Figure	  6.	  4q25	  risk	  variants,	  Pitx2	  deficiency	  and	  calcium	  homeostasis.	  	  
A	   Pitx2c	   levels	   in	   the	   common	   combinations	   of	   the	   4q25	   variants	   rs2200733,	   rs13143308	   and	  
rs1448818,	   indicated	  below	  bars	  B	   Right	   atrial	  myocytes	   from	  a	   Pitx2fl/fl	   and	   a	   Pitx2fl/-­‐	  mouse	  with	  
indication	  of	  spark	  sites.	  Calcium	  traces	  from	  each	  site	  are	  shown	  to	  the	  right.	  Insets	  show	  details	  of	  
the	  calcium	  sparks.	  Spark	  densities	  are	  shown	  on	  the	  right	  (unpaired	  t-­‐test).	  C	  Membrane	  potential	  
recordings	  in	  Pitx2fl/fl	  (top)	  and	  Pitx2fl/-­‐	  mice	  (bottom).	  Traces	  are	  amplified	  on	  the	  right.	  D	  Frequency	  
of	  spontaneous	  action	  potentials	  (events·∙min-­‐1)	  at	  resting	  potentials	  given	  below	  bars	  (8	  Pitx2fl/-­‐	  and	  
8	   Pitx2fl/fl	   mice).	   Pitx2	   deficiency	   significantly	   affected	   the	   spontaneous	   AP-­‐frecuency	   (p<0.05,	  
ANOVA).	  E	  Afterdepolarizations	  (black	  asterisks)	  in	  myocytes	  from	  Pitx2fl/-­‐	  mice	  paced	  at	  0.5	  Hz	  (left)	  
and	   3	   Hz	   (right).	   The	   red	   asterisk	   indicates	   an	   action	   potential	   diminished	   by	   a	   preceding	  
afterdepolarization.	  Arrows	  indicate	  stimulation	  pulses	  and	  dashed	  lines	  0	  mV.	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Age	  (years)	   68.0±0.8	   66.7±0.8	   	  	  	  0.8	  
Height	  (cm)	  	   164.2±0.9	   164.2±0.7	   	  	  	  0.9	  
Weight	  (kg)	  	   76±1	   75±1	   	  	  	  0.6	  
Cardiovascular	  disease	  %	  (n)	   	   	   	  
Arterial	  hypertension	  	   	  	  	  	  	  67	  (117)	   	  	  	  	  	  74	  (78)	   	  	  	  0.2	  
Diabetes	  	   	  	  	  	  	  40	  (69)	   	  	  	  	  	  30	  (32)	   	  	  	  0.12	  
Aortic	  valve	  disease	  	   	  	  	  	  	  49	  (85)	   	  	  	  	  	  57	  (60)	   	  	  	  0.2	  
Mitral	  valve	  disease	   	  	  	  	  	  26	  (45)	   	  	  	  	  	  22	  (23)	   	  	  	  0.5	  
Tricuspid	  valve	  disease	   	  	  	  	  	  13	  (23)	   	  	  	  	  	  	  	  9	  (10)	   	  	  	  0.4	  
Ischaemic	  heart	  disease	   	  	  	  	  	  62	  (108)	   	  	  	  	  	  53	  (56)	   	  	  	  0.14	  
Echocardiography	   	   	   	  
Left	  atrial	  diameter	  (mm)	   46.6±1.0	   44.6±1.2	   	  	  	  0.2	  
Left	  atrial	  diameter	  index	   2.61±0.07	   2.47±0.08	   	  	  	  0.2	  
LVEF	  (%)	   55.2±1.1	   58.0±1.3	   	  	  	  0.11	  
Pharmacological	  treatment	  %	  (n)	   	   	   	  
ACE-­‐inhibitors	   	  	  	  	  	  41	  (72)	   	  	  	  	  	  35	  (38)	   	  	  	  0.4	  
ARB	   	  	  	  	  	  20	  (34)	   	  	  	  	  	  21	  (23)	   	  	  	  0.8	  
β-­‐Blockers	   	  	  	  	  	  52	  (90)	   	  	  	  	  	  56	  (59)	   	  	  	  0.4	  
Calcium	  antagonists	   	  	  	  	  	  21	  (38)	   	  	  	  	  	  25	  (27)	   	  	  	  0.6	  
Nitrates	   	  	  	  	  	  25	  (44)	   	  	  	  	  	  25	  (26)	   	  	  	  1	  
Dicoumarin	   	  	  	  	  	  20	  (35)	   	  	  	  	  	  29	  (31)	   	  	  	  0.08	  
Acetyl	  salicylic	  acid	   	  	  	  	  	  41	  (72)	   	  	  	  	  	  43	  (46)	   	  	  	  0.8	  
Statins	   	  	  	  	  	  60	  (105)	   	  	  	  	  	  68	  (72)	   	  	  	  0.3	  
	   	   	   	   	   	  
TABLE	   1.	   Clinical	   characterization	   of	   the	   patients	   included	   in	   electrophysiological	   and	  molecular	  
biological	   analyses.	   LVEF,	   left	   ventricular	   ejection	   fraction;	   ACE-­‐inhibitors,	   angiotensin	   converting	  
enzyme	   inhibitors;	   ARB	   angiotensin	   receptor	   blockers;	   Values	   are	   mean	   ±	   standard	   deviation	   or	  
percentage	  and	  number	  (n)	  of	  patients	  with	  the	  condition.	  P-­‐values	  for	  differences	  between	  Normal	  
and	  Risk	  groups	  are	  given	  on	  the	  right.	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P	   0.004	   0.09	   	   0.72	   0.19	   	   0.73	   0.22	   	  
	  
Table	   2.	   Effect	   of	   rs13143308	   variants	   on	   ITI	   frequency,	   SR	   calcium	   Load,	   and	   NCX	   activity	   in	  
patients	  without	  (No	  AF)	  and	  with	  AF.	  The	  ITI	  frequency	  is	  given	  in	  events/min,	  the	  SR	  calcium	  load	  in	  
amol/pF,	  and	  the	  NCX	  activity	  in	  s-­‐1.	  P-­‐values	  for	  comparison	  of	  Normal	  and	  Risk	  variants	  are	  given	  in	  
columns	  to	  the	  right	  of	  each	  comparison.	  Risk	  refers	  to	  the	  presence	  of	  at	  least	  one	  rs13143308T	  risk	  
allele.	   Normal	   refers	   to	   patients	   with	   normal	   rs2200733C	   and	   rs13143308G	   alleles.	   P-­‐values	   for	  
comparison	  of	  No	  AF	  and	  AF	  are	  given	  below.	  
 
